Catalyst Wire Dossier Catalyst Wire Dossier

Dalazatide (ShK-186)

ShK-186 · Kineta Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dalazatide (ShK-186), covering 2015-05-06 to 2015-05-06. Get the full timeline:

Most recent: Clinical Trial Update: A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis [Phase 1]

See pricing